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Abstract : The levels of interleukin-1beta,
tumour necrosis factor-alpha, and interleukin
6 in gingival crevicular fluid of phenytointreated patients (from sites exhibiting
overgrowth and sites not exhibiting
overgrowth) and control subjects were
investigated. Six epileptic patients exhibiting
severe
phenytoin-induced
gingival
overgrowth, 12 patients with chronic
gingivitis and 11 subjects with clinically
healthy periodontium were included in the
study. The cytokine levels were analysed by
enzyme-linked immunosorbent assay and
expressed as ng/2 sites. Wilcoxon signed-rank
test, Kruskall-Wallis, Mann-Whitney U test
and Spearman rank correlation were used for
statistical analysis of the data. Overgrown
sites showed significantly higher levels of
interleukin-1beta compared to the healthy
and gingivitis sites (p=0.0009, p=0.049

1

Department of Periodontology, Faculty of
2
Dentistry, Department of Paediatrics, Faculty
of Medicine, Ege University, ‹zmir - TURKEY

Introduction
Phenytoin (PHT) is an anti-convulsant drug commonly
used in the management of epilepsy. PHT treatment is
likely to cause a broad spectrum of side effects, including
skeletal, hepatic, immunological, and connective tissue
disturbances (1). Each year up to 50 per cent of an
estimated two million people taking PHT for prevention
of seizures develop severe gingival overgrowth and
require surgical intervention. The exact cellular/molecular
mechanism of this side effect remains unclear (2). It was
proposed that PHT could react with a phenotypically
distinct subpopulation of gingival fibroblasts and cause an
increase in protein synthesis and cell proliferation rate
(3). Furthermore, Dill et al. (4) and Iacopino et al. (5)
have suggested that PHT may promote drug-induced
gingival overgrowth by altering macrophage phenotype,
which results in an increased production of cytokines or
growth factors.
Interleukin-1beta (IL-1β) and tumour necrosis factoralpha (TNF-α) are inflammatory cytokines mainly
secreted by activated monocyte/macrophages (6). IL-1β

respectively). However, the difference was
not
statistically
significant
between
overgrown and non-overgrown sites in
epileptic patients (p=0.1159). Tumour
necrosis factor-alpha values did not reveal any
significant difference among the study
groups. For interleukin 6, the highest value
was found in the gingivitis sites, followed by
overgrown, non-overgrown, and healthy
sites, in descending order. No correlation was
found between gingival crevicular fluid
cytokine levels and papilla bleeding index
values in phenytoin-treated patients. The
results suggest that these cytokines play an
indirect role in the complex mechanism of
phenytoin-induced gingival overgrowth.
Key Words: phenytoin, interleukin-1beta,
tumour necrosis factor-alpha, interleukin-6,
gingival crevicular fluid

and TNF-α possess various biological effects, including
induction of fibroblast growth and synthesis of matrix by
fibroblasts (7), and also production of collagenase (8).
Interleukin-6 (IL-6) is a major mediator of host response
to tissue injury and infection (9). This cytokine plays a
major role in B-cell differentiation and fibroblast growth
inhibition. It has been suggested (10) that IL-6 interferes
with functions of various cytokines, which stimulate
fibroblast activity (11). Recently, it was reported that
TNF-α induces IL-1β production (12) and prostaglandin
E2 formation in gingival fibroblasts that was upregulated
by PHT (13). In another in vitro study it was found that
both IL-1β and PHT reduce the expression of α 1 (I)
procollagen mRNA in gingival fibroblasts (14). In light of
these findings, it may be hypothesised that an interaction
between PHT and cytokines plays a role in the mechanism
of drug-induced gingival overgrowth. Therefore, the
present study was planned in order to investigate the
quantities of IL-1β, TNF-α and IL-6 in the gingival
crevicular fluid (GCF) of patients with PHT-induced
gingival overgrowth.
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Materials and Methods
Patient selection
Six epileptic patients followed by the Department of
Neurology, Faculty of Medicine, Ege University, exhibited
severe gingival overgrowth requiring periodontal surgery
together with gingivitis. All of these patients (4 female, 2
male) (mean age 25.83±0.41 years) had been taking
PHT for ≥ 6 months without any recent change in the
therapeutic dosage. Twelve patients (7 female, 5 male)
(mean age 30.4±11 years) with gingivitis and 11 subjects
(5 females, 6 males) (mean age 30.8±9.5 years) with
clinically healthy periodontium were included in the study
as controls. There was no history of any other systemic
disease in the epileptic patients and no treatment with
drugs known to induce gingival overgrowth in any of the
subjects in the two control groups. Clinical recordings
including plaque index (PI) (15), papilla bleeding index
(PBI) (16) and hyperplastic index (HI) (17) were
performed prior to any periodontal intervention. The
degree of gingival overgrowth was classified in 4
categories based on the criteria of Angelopoulos and Goaz
(18) as modified by Pernu et al. (17) Those PHT-treated
patients who had moderate or severe gingival
overgrowth were included in this study. Radiographically,
there was no evidence of alveolar bone loss in any of the
subjects participating in the study.
GCF sampling and cytokine analysis
In total, 70 GCF samples from 29 people were
collected from the following sites in four groups: Group
1, PHT GO+ sites (2 sites with PHT-induced gingival
overgrowth in each PHT-treated patient); group 2, PHT
GO- sites (2 sites without PHT-induced gingival
overgrowth in each PHT-treated patient); group 3,
gingivitis sites (2 inflamed sites in each gingivitis patient,
with a PBI score of ≥1), group 4, healthy sites (2 clinically
healthy sites from each periodontally healthy subject).
Informed consent was obtained from all the subjects
before they were included in the study protocol.
Supragingival plaque was removed by sterile curettes
and, after air-drying, the surfaces were isolated by cotton
rolls. Mechanical irritation was avoided and strips
contaminated with blood were discarded. GCF samples
were obtained by inserting filter paper strips (Periopaper,
ProFlow Inc., Amityville, NY) for 30 seconds into
interproximal sites from the buccal aspects of the relevant
teeth. Collected GCF volume was determined by
Periotron 6000 (Harco Electronics Ltd., Winnipeg,
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Manitoba, Canada) and the strips were placed in sterile
polypropylene tubes before freezing at -40ºC. Cytokine
levels in GCF samples were analysed by using enzymelinked immunosorbent assay (ELISA) and the relevant
ELISA kits; RPN2141, RPN2148, and RPN2145
(Amersham Int. Buckinghamshire, UK).
As previously described, (19), GCF samples were
eluted from the strips by placing them in 400 µl of
PBS/0.1%BSA/0.05%thimerosal for 18 hours at 4ºC.
The results were expressed as ng/2 sites.
Statistical analysis
Statistical analysis was performed by non-parametric
techniques. Wilcoxon signed-rank test (confidence
interval of p<0.05) was used to compare the clinical
recordings and the cytokine levels between the PHT GO+
and PHT GO- sites. Kruskall-Wallis test was used to
compare the PHT groups with gingivitis and clinically
healthy control groups. In the presence of significant
difference (p<0.05), Bonferroni-corrected Mann-Whitney
U test was used for pair-wise comparisons. Additionally,
the correlation between mean values of GCF IL-1β, TNFα, and IL-6 levels in PHT-treated patients and PBI scores
were assessed by Spearman rank correlation.
Results
Mean values of clinical measurements are listed in
Table 1. While the GCF volumes in PHT GO+ and
gingivitis sites were much the same, those of healthy and
PHT GO- sites were significantly lower. No statistically
significant age difference was found between the groups.
PI and PBI values at PHT GO- sites were significantly
lower compared to the values of PHT GO+ and gingivitis
sites. Both of the PHT groups (PHT GO+ sites and PHT
GO- sites) showed significantly higher scores of PBI and
PI when compared with those of clinically healthy sites (all
the p values were 0.0000). PBI scores at the PHT GO+
sites were also significantly higher than those of the PHT
GO- sites (p=0.03).
The mean IL-1β value at the PHT GO+ sites was higher
than those of the other groups (Fig. 1). PHT GO+ sites
showed significantly higher levels of IL-1β compared to
the healthy and gingivitis sites (p=0.0009, p=0.049
respectively). However, the difference was not statistically
significant between the PHT GO+ and PHT GO- sites
(p=0.1159). Moreover, IL-1β levels at the PHT GO- sites
were significantly higher than those of the healthy sites
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Group

Age

Gingivitis
Healthy
PHT GO+
PHT GO-

30.4±11
30.8±9.5
25.8±16.4
25.8±16.4

GCF volume
µl (2 samples)

PI

0.93±0.24
0.26±0.17
0.91±0.21***
0.68±0.19

HI

1.79±0.6
0.2±0.4
1.73±0.5
1 ±0.63

PBI

0.83±0.6
0
2.06±0.1**
0.2±0.1

Table 1.

Clinical values of the study groups.

2.08±0.9
0.1±0.05
2.27±0.72*
1.15±0.54

*

p=0.03 between PHT GO+ and PHT GO-, p=0.0000 between PHT GO+ and clinically
healthy sites
** p=0.000 between PHT GO+ and clinically healthy sites
*** For GCF volume all the differences were significant except that between PHT GO+ and
gingivitis sites. p=0.0464 between PHT GO+ and PHT GO- sites.
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between the PHT GO+ and gingivitis sites (p=0.1740) and
between the PHT GO+ and PHT GO- sites (p=0.0747)
were not statistically significant. No correlation was found
between PBI values and GCF cytokine levels in PHTtreated patients (p>0.05) (Table 2).

*

IL-1beta (ng/2 sites)
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Figure 1.
*

**

Healthy

PHT GO+

PHT GO-

The amounts of IL-1β in the study groups (mean±standard
deviation).
Significant differences between the PHT GO+ group and
the gingivitis and healthy control groups (p=0.049, and
p=0.0009 respectively).
Significant difference between the PHT GO- group and the
healthy group (p=0.0009).

(p=0.0009), while they were similar to those of the
gingivitis sites (p=0.8514). TNF-α values did not reveal
any statistically significant difference between the four
study groups (Fig. 2). The highest IL-6 levels were found
at the gingivitis sites, followed by PHT GO+, PHT GO-,
and healthy sites respectively (Fig. 3). Mean IL-6 levels
were statistically different between the gingivitis and PHT
GO- sites (p=0.0099), and between the PHT GO+ and
healthy sites (p=0.0074). However, the differences

Discussion
Drug-induced gingival overgrowth starts at
interproximal sites. GCF, which is fundamentally a serum
exudate, reflects the biochemical events in the
interproximal tissues. Thus, in the present study, cytokine
levels were analysed in GCF samples obtained from
interproximal sites. The increase in GCF volume might
result in a false decrease in cytokine concentration of GCF
samples (20). Therefore, total GCF cytokine amounts per
standard sampling time might be a better indicator of
relative GCF constituent activity than GCF concentration
(21). For this reason, the total amounts rather than the
concentrations of cytokines were evaluated in this study.
Considering the possible individual variability, the
epileptic patients under PHT treatment who did not
exhibit any PHT-induced gingival overgrowth were not
included. Instead, GCF samples were obtained from sites
not exhibiting gingival overgrowth in patients who had
severe PHT-induced gingival overgrowth and made up
one control group. The present preliminary study is to
our knowledge the first report of an investigation of
cytokine levels in the GCF of PHT-treated patients.
Hence, we were unable to compare our data with similar
studies.
In PHT-induced gingival overgrowth, a relative
increase in the amount of proteoglycans along with a
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2

1.5

1

0.5

0
Gingivitis
Figure 2.

Healthy

PHT GO +

PHT GO -

The amounts of TNF-α in the study groups (mean±standard
deviation). No significant difference was found between the
study groups (p>0.05).
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Figure 3.

Healthy

PHT GO -

The amounts of Il-6 in the study groups (mean±standard
deviation). There were statistically significant differences
between the PHT GO+ group and the healthy group
(p=0.0074), and between the PHT GO- group and
gingivitis group (p=0.0099). The differences between the
PHT GO+ and the gingivitis group, and between the PHT
GO+ and the PHT GO- group were not significant
(p>0.05).

Table 2.

Correlations between the cytokine levels in GCF and PBI
scores in PHT-treated patients.
IL-1β

PBI

PHT GO +

TNF-α

IL-6

r

p

r

p

r

p

0.273

0.389

0.298

0.346

0.427

0.165

No correlation was found between GCF cytokine levels and PBI scores
in PHT–treated patients (p>0.05).
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relative decrease in collagen content is a characteristic
finding (22). It is known that IL-1 inhibits procollagen I
synthesis by fibroblasts and this inhibitory effect is
potentiated by PHT (14). On the other hand, IL-1 induces
non-collagenous matrix synthesis in gingival connective
tissue (22). These interactions support the postulate that
IL-1β may be an important component of PHT-induced
gingival overgrowth. TNF-α has immunological and
inflammatory effects similar to those of IL-1. Moreover,
TNF-α induces IL-1 (12) and PGE2 (13) synthesis by
gingival fibroblasts and this effect is also potentiated by
PHT. IL-6 is secreted in higher amounts in sites of
inflammation and has biological influences on periodontal
tissue destruction (2 ). Brunius et al. (23) have suggested
that PHT-potentiated upregulation of IL-1β production in
the presence of TNF-α may be important in the
pathogenesis of drug-induced gingival overgrowth. In the
present study, the GCF IL-1β and IL-6 levels at PHT GO+
sites were higher than those at the PHT GO- sites; hence
our findings are in line with their report. This finding may
contribute to an alteration in the composition of
connective tissue. Iacopino et al. (5) did not find any
increase in the level of IL-1β mRNA in the gingival tissues
of PHT-treated patients exhibiting gingival overgrowth.
They attributed this to the variability of macrophage
phenotypes in various clinical conditions. In spite of the
rather small number of patients in the PHT-induced
gingival overgrowth group, the quantitative analysis of
the present study implies a possible role of inflammatory
cytokines in drug-fibroblast interactions. This has been
suggested before by Seymour et al. (2) and our findings
are consistent with their report.
In the present study, GCF cytokine levels were high at
both PHT GO+ and PHT GO- sites, which exhibited
varying degrees of clinical inflammation. However, we
found higher level of IL-1β in PHT GO+ sites compared to
the gingivitis sites, although they were similar in clinical
inflammation. Furthermore, IL-6 levels were lower at the
PHT GO+ sites than in the gingivitis sites. The high level
of IL-1β in the PHT GO+ group may well be related also
to the present inflammation. Nevertheless, since there
was no correlation between PBI scores and GCF cytokine
levels in PHT-treated patients, this increase cannot be
solely explained by the gingival inflammation. It has been
postulated that IL-6 functions as an inhibitor of cytokines,
which stimulate fibroblastic activity (11). A recent study
of ours revealed statistically low GCF IL-6 levels at
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inflamed cyclosporine A GO+ sites compared to the
gingivitis sites (24). It may be suggested that, similar to
cyclosporine A, PHT causes a reduction in GCF IL-6 levels
and thereby removes its inhibitory effect, and this
reduction in GCF IL-6 level may be effective in the
occurrence of PHT-induced gingival overgrowth.
The lack of a statistically significant difference
between the PHT GO+ and PHT GO- groups with regard
to the IL-1β and IL-6 levels may stem from the small
number of cases present in these groups. Due to the
limited number of PHT-induced gingival overgrowth
cases, it was not possible to make a distinction with
regard to the degree of gingival inflammation. Marked
inter-individual variation in PHT pharmacokinetics (25)
and fibroblast heterogeneity (26,27) may play a role in
the pathogenesis of this side effect.
In conclusion, together with some other factors, the
alteration of GCF IL-1β and IL-6 levels might act as
cofactors for inducing gingival overgrowth in PHTtreated patients. The pathogenic mechanisms in the
background of PHT-induced gingival overgrowth seem to

be complex and multifactorial. Comprehensive studies
including more cases of PHT-induced gingival overgrowth
may provide more information about the mechanism of
drug-induced gingival overgrowth. A better
understanding of the mechanism of this side effect may
eventually lead to modification of drugs in this category
and/or development of new alternatives which do not act
in the same way. This side effect is extremely important
for those patients who have to take PHT all their lives. If
and when this side effect can be avoided, the patients will
be able to achieve improved oral hygiene, better
aesthetics, and more comfortable mastication.
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